Skip to main content

Table 4 Nab-paclitaxel-containing regimens for metastatic breast cancer

From: Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial

Study Regimen Study design and setting Number of patients Overall response rate Median time to progression/progression-free survival (months) Median overall survival (months)
Our study Nab-paclitaxel 125 mg/m2+ GEM 800 mg/m2, days 1, 8, 15, q4w Phase II,all lines 84 52.40% 7.9 25.8
Gradishar et al. [3] Nab-paclitaxel 260 mg/m2,q3w Phase III,all lines 229 33% 23.0(weeks) NR
Paclitaxel 175 mg/m2,q3w 225 19% 16.9(weeks) NR
Gradishar et al. [14] Nab-paclitaxel 300 mg/m2,q3w Phase II, first-line 76 37% 11 27.7
Nab-paclitaxel 100 mg/m2 weekly, days 1, 8, 15, q4w 76 45% 12.8 22.2
Nab-paclitaxel 150 mg/m2 weekly, days 1, 8, 15, q4w 74 49% 12.9 33.8
Docetaxel 100 mg/m2,q3w 74 35% 7.5 26.6
Roy et al. [6] Nab-paclitaxel 125 mg/m2 weekly, days 1,8,q3w + GEM 1000 mg/m2 weekly, days 1,8,q3w Phase II, first-line 50 50% 7.9 NR
Lobo et al. [7] Nab-paclitaxel 150 mg/m2 + GEM 1500 mg/m2 + bevacizumab 10 mg/kg,day 1,15,q4w Phase II, first-line, TNBC 30 75.90% 10.4 NR
Sun et al. [13] Nab-paclitaxel 125 mg/m2, days 1, 8, 15+ DDP 75 mg/m2, q4w Phase II,all lines 73 67.10% 9.8 26.9
  1. Abbreviations: q3w: every 3 weeks, GEM: gemcitabine, DDP: cisplatin, TNBC: tri-negative breast cancer